Stable Disease — Unchanged Tumor Measurement

Under standardised response evaluation frameworks, such as RECIST (Response Evaluation Criteria in Solid Tumours), stable disease reflects a measurable maintenance of the status quo. To meet this criterion, the sum of target lesion diameters must neither decrease by at least 30% (which would signify a partial response) nor increase by 20% or more (which defines progressive disease).

Additionally, the classification requires that no definitive new lesions have formed and non-target lesions show no clear evidence of progression. In modern oncology, particularly with cytostatic targeted agents and immunotherapy, stable disease can represent durable therapeutic efficacy, maintaining disease equilibrium and preserving functional status.

Stable disease is an important clinical milestone that usually supports continuing the current treatment regimen. For patients living with advanced or metastatic disease, long periods of stable disease (disease control) often correlate with improved progression-free survival and overall survival. Recognising stable disease helps reassure patients and caregivers that the absence of dramatic tumor shrinkage does not equal treatment failure; halting progression is a valid therapeutic goal.

Stable disease is determined by comparing baseline and follow-up imaging studies, such as contrast-enhanced CT, MRI, or PET-CT, using standardised criteria like RECIST 1.1 or iRECIST. Serum tumor markers (such as CEA, CA 19-9, or PSA) are often monitored alongside imaging to corroborate disease stability.

Stable disease is a standard response evaluation category across all solid tumors, including advanced colorectal, lung, breast, renal cell, and prostate cancers. It is especially common in slower-growing cancers such as neuroendocrine tumors, gastrointestinal stromal tumors (GIST), and low-grade sarcomas.

Achieving stable disease generally leads oncologists to continue the existing treatment, such as maintenance chemotherapy, targeted biological therapies, or endocrine therapies, provided the patient tolerates side effects well. If stability is accompanied by unacceptable toxicities, doctors may consider treatment holidays or dose modifications.